IPDA for High-Priority HIV-1 Subtypes to Enable Global Eradication Trials
Award Notice Posted
- Solicitation number
- PHS-2020-1
- Agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Awarded
- to Accelevir Diagnostics LLC
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75N93020C00015 Federal contract award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- PSC
- Not on record
Notice details come from SAM.gov. Updated .
About this opportunity
AcceleVir Diagnostics, LLC was awarded a one-year, $299,975 contract by the National Institute of Allergy and Infectious Diseases to conduct research on high-priority HIV-1 subtypes that are important to global clinical trials aimed at potentially eradicating HIV/AIDS worldwide. The contract number 75N93020C00015 was awarded on September 25, 2020 to facilitate the contractor's work on HIV-1 subtypes to enable these global clinical research efforts.
Notice text
Awarded contract 75N93020C00015 to ACCELEVIR DIAGNOSTICS, LLC for 299975.00 on 2020-06-01.
Notice history
5 of 7 notices listed here. See the rest on GovTribe.
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity